Propolis + Royal Jelly: Gentle Modulation of Blood Lipids and Inflammation
2026-11-17
Royal jelly and propolis are both bee products, and their combination has preliminary clinical evidence in the area of cardiometabolic risk. Royal jelly is a milky-white substance secreted by the hypopharyngeal glands of worker bees and is rich in proteins, fatty acids (such as 10-hydroxy-2-decenoic acid, 10-HDA), and other components; it has been repeatedly studied in lipid metabolism and inflammation regulation. Propolis has anti-inflammatory, antioxidant, and lipid-regulating potential. Combining the two is intended to act jointly on cardiovascular risk markers through multiple pathways, consistent with the approach of “maintaining metabolic homeostasis through dietary support.”
I. Clinical Evidence for the Combination: Preliminary Signal in Dialysis Patients
Kemp et al. (2025) conducted a randomized, double-blind, placebo-controlled trial in hemodialysis patients. Thirty-eight patients were assigned to a royal jelly + green propolis group (EPP-AF®, 100 mg royal jelly + 500 mg green propolis) or a placebo group for 2 months. Results showed that plasma IL-6 decreased from 0.78 to 0.63 pg/mL (p=0.008) and total cholesterol decreased from 138.60 to 111.85 mg/dL (p=0.03) in the treatment group, with no corresponding changes in the placebo group. The study suggests that this combination may serve as a non-pharmacological strategy for reducing cardiovascular risk markers. However, the participants were dialysis patients, so generalization of the conclusions to the general population should be cautious, and the intervention period was relatively short.
Notably, a new clinical trial in patients with coronary artery disease (CAD) (NCT07596992) was launched in 2026 to evaluate the effects of propolis and royal jelly on metabolomic profiles, inflammation, and cardiovascular risk markers, with completion expected in 2028. This will provide new data to build evidence for the combination in non-dialysis cardiovascular populations.
II. Evidence for Royal Jelly Alone: Support on Both Lipid and Inflammatory Dimensions
Human evidence for royal jelly alone also supports its association with metabolic indicators. Petelin et al. (2019) conducted a randomized, double-blind, placebo-controlled trial in 60 asymptomatic overweight adults (n=30 each, 8-week intervention) and found that royal jelly supplementation reduced total cholesterol by 6.7% (p=0.041) and C-reactive protein by 19% (p=0.027), while increasing adiponectin by 34% (p=0.011) and serum total antioxidant capacity by 54% (p=0.005). These results provide evidence for royal jelly as a supportive component for metabolic health from both lipid and inflammatory dimensions, and indirectly support its potential additive value when combined with propolis.
III. Broader Evidence: Umbrella Review of Bee Products and Cardiometabolic Health
Broader evidence comes from reviews and pooled analyses. Norouzzadeh et al. (2025) published an umbrella review summarizing 69 RCTs with 3,544 participants; the results showed that royal jelly improved blood pressure, lipid profile, glycemic indicators, and total antioxidant capacity, while propolis improved anthropometric indices, lipids, blood glucose, liver enzymes, and markers of inflammation and oxidative stress. The study used the GRADE framework to assess evidence quality and noted that royal jelly and propolis, at appropriate doses, have dose-dependent benefits for cardiometabolic health.
A meta-analysis by Zhang et al. (2025) from a Chinese team included 12 RCTs (731 participants) and further supported mild beneficial effects of propolis on glycemic, lipid, and inflammatory indicators in people with type 2 diabetes: HDL-C increased significantly; LDL-C and triglycerides decreased significantly; fasting blood glucose, HOMA-IR, and HbA1c all improved; and CRP decreased significantly. However, no significant changes were observed in total cholesterol, TNF-α, IL-6, SOD, MDA, or other indicators.
Overall, the value of propolis + royal jelly lies in “supportive modulation”—helping maintain stable levels of markers such as lipids and inflammation—rather than treating diagnosed cardiovascular disease.
IV. Scope of Application and Usage Precautions
Positioning: This combination is better understood as a dietary support option in chronic metabolic risk management, intended for people concerned about blood lipid and inflammation levels. It cannot replace standard lipid-lowering, blood pressure-lowering, or glucose-lowering treatment, nor should it be promoted as a means of preventing or treating cardiovascular disease.
Population boundaries: People with established cardiovascular disease or diabetes, or those taking related medications, should consult their attending physician before introducing any bee product supplement to avoid interactions with existing treatment; both royal jelly and propolis are bee products, so caution is advised for people allergic to bee products. Current evidence is mainly based on dialysis and overweight populations; the optimal dose and long-term safety for the general healthy population still require further study.
Daily use: Products are mainly available as capsules and oral liquids. Royal jelly is relatively sensitive to freshness, and storage and transport conditions affect the stability of its active components. It is recommended to incorporate it into a dietary management framework as a supplement to, not a replacement for, standard treatment.
Compliance note: The evidence level for this area is moderate, and study samples are limited; propolis + royal jelly are foods/health foods and must not be claimed to prevent or treat cardiovascular disease, nor can they replace standard treatment; caution is advised for people allergic to bee products.
Propolis + royal jelly show preliminary potential for supportive modulation in cardiometabolic risk management, but existing evidence comes mostly from specific populations, and data on the combination remain limited. It is more suitable as a dietary support option and cannot replace standard treatments such as lipid-lowering, blood pressure-lowering, or glucose-lowering therapy. Evidence boundaries should be viewed rationally; patients with chronic diseases and people allergic to bee products should consult a doctor before use.
References
[1] Kemp JA, Mendonça M, Chrispim P, Ribeiro M, Britto I, Coutinho-Wolino KS, Ribeiro-Alves M, Nakao LS, Kussi F, Coelho EB, Berretta AA, Mafra D, Cardozo L. Apitherapy with Royal Jelly and Green Propolis EPP-AF Improves Cardiovascular Risk Markers in Patients Undergoing Hemodialysis. Toxins (Basel). 2025;17(8):369.
[2] Norouzzadeh M, Barazandeh S, Hasan Rashedi M, Jamshidi S, Hatamifar F, Maghsoomi Z, Teymoori F, Malek M. Dosage exploration of the effects of honey and its derivatives on cardiometabolic outcomes: an overview of systematic reviews and GRADE-assessed updated meta-analysis. Nutr Diabetes. 2025;15(1):48.
[3] Petelin A, Kenig S, Kopinč R, Deželak M, Černelič Bizjak M, Jenko Pražnikar Z. Effects of Royal Jelly Administration on Lipid Profile, Satiety, Inflammation, and Antioxidant Capacity in Asymptomatic Overweight Adults. Evid Based Complement Alternat Med. 2019;2019:4969720.
[4] Zhang Y, Ding S, Li W, Wang X, Lv J, Niu Q, Zhang Q. Propolis effects on blood sugar and lipid metabolism, inflammatory indicators, and oxidative stress in people with type 2 diabetes: a systematic review and meta-analysis. Front Nutr. 2025;12:1653730.
Previous Page:
Real-time Blog
Upcoming Exhibitions for 2026...
2026-01-30